Top

Published in:

01-05-2016 | Original Article

Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients

Authors: Xin Wei, Yangqiu Jin, Yinpu Tian, Huiyuan Zhang, Jie Wu, Wei Lu, Xiaofen Lu

Published in: Tumor Biology | Issue 5/2016

Abstract

Multiple factors in the tumor microenvironment were found to inhibit antitumor adaptive immune responses, allowing tumor persistence and growth. In this study, ascites from ovarian cancer patients were collected. We observed that a population of interleukin-10⁺ B (IL-10⁺ B) cells was preferentially enriched in the ascites. This population was associated with naive B cell phenotype or IgM or class-switched memory B cell phenotypes. The frequencies of IL-10⁺ B cells were negatively correlated with the frequencies of interferon gamma-producing (IFN-g⁺) CD8⁺ T cells and were positively correlated with the frequencies of Foxp3⁺ CD4⁺ T cells. To examine whether increased IL-10⁺ B cells in ascites could directly result in increased suppression of IFN-g production by CD8⁺ T cells, we cocultured CD8⁺ T cells with autologous blood B cells or ascitic B cells and found that CD8⁺ T cells cocultured with ascitic B cells demonstrated significantly suppressed IFN-g production. This suppression was in part mediated by IL-10 as well as low CD80/CD86 expression, since depletion of IL-10 and stimulation of CD28 partially reverted IL-10⁺ B cell-mediated suppression. Together, these data demonstrated an additional regulatory mechanism in the tumor microenvironment, which utilizes IL-10⁺ B cells.

Brichard VG, Lejeune D. GSK’s antigen-specific cancer immunotherapy programme: pilot results leading to phase III clinical development. Vaccine. 2007;25:B61–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17916463.CrossRefPubMed

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–7.CrossRefPubMed

Topalian SL, Hom SS, Kawakami Y, Mancini M, Schwartzentruber DJ, Zakut R, et al. Recognition of shared melanoma antigens by human tumor-infiltrating lymphocytes. J Immunother. 1992;12:203–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1445813.CrossRefPubMed

Monach PA, Meredith SC, Siegel CT, Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity. 1995;2:45–59. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7600302.CrossRefPubMed

Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5:200ra116. Available from: http://stm.sciencemag.org/content/5/200/200ra116.CrossRefPubMedPubMedCentral

Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–7. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved; Available from: http://dx.doi.org/10.1038/nature14011.CrossRefPubMedPubMedCentral

Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. 2013;25:214–21. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3636159&tool=pmcentrez&rendertype=abstract.CrossRefPubMedPubMedCentral

Nishikawa H, Jäger E, Ritter G, Old LJ, Gnjatic S. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood. 2005;106:1008–11.CrossRefPubMed

Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49–61. Elsevier. Available from: http://www.cell.com/article/S1074761314002301/fulltext.CrossRefPubMedPubMedCentral

10.

Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Plüddemann A, et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006;176:5023–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16585599.CrossRefPubMed

11.

Marchetti C, Pisano C, Facchini G, Bruni GS, Magazzino FP, Losito S, et al. First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Rev Anticancer Ther. 2010;10:47–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20014885.CrossRefPubMed

12.

Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27—memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012;18:3281–92.CrossRefPubMed

13.

Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev. 2008;222:101–16. Available from: http://onlinelibrary.wiley.com.ezproxy.library.uvic.ca/doi/10.1111/j.1600-065X.2008.00614.x/abstract.CrossRefPubMed

14.

Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:18538–43.CrossRefPubMedPubMedCentral

15.

Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity. 2010;32:129–40. Available from: http://www.hubmed.org/display.cgi?uids=20079667.CrossRefPubMed

16.

Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol. 2010;185:4977–82.CrossRefPubMed

17.

Sayi A, Kohler E, Toller IM, Flavell RA, Müller W, Roers A, et al. TLR-2-activated B cells suppress Helicobacter-induced preneoplastic gastric immunopathology by inducing T regulatory-1 cells. J Immunol. 2011;186:878–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21149607.CrossRefPubMed

18.

Mangan NE, Fallon RE, Smith P, van Rooijen N, McKenzie AN, Fallon PG. Helminth infection protects mice from anaphylaxis via IL-10-producing B cells. J Immunol. 2004;173:6346–56.CrossRefPubMed

19.

Gray M, Miles K, Salter D, Gray D, Savill J. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. Proc Natl Acad Sci U S A. 2007;104:14080–5.CrossRefPubMedPubMedCentral

20.

Lemoine S, Morva A, Youinou P, Jamin C. Human T cells induce their own regulation through activation of B cells. J Autoimmun. 2011;36:228–38. Available from: http://dx.doi.org/10.1016/j.jaut.2011.01.005.CrossRefPubMed

21.

Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. Cancer Res. 2011;71:3505–15. Available from: http://cancerres.aacrjournals.org/content/71/10/3505.full.CrossRefPubMedPubMedCentral

22.

Inoue S, Leitner WW, Golding B, Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 2006;66:7741–7. Available from: http://www.hubmed.org/display.cgi?uids=16885377.CrossRefPubMed

23.

Liu J, Zhan W, Kim CJ, Clayton K, Zhao H, Lee E, et al. IL-10-producing B cells are induced early in HIV-1 infection and suppress HIV-1-specific T cell responses. PLoS One. 2014;9(2):e89236. Available from: http://www.hubmed.org/display.cgi?uids=24586620.CrossRefPubMedPubMedCentral

24.

Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008;118:3420–30.PubMedPubMedCentral

25.

Das A, Ellis G, Pallant C, Lopes ARR, Khanna P, Peppa D, et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol. 2012;189:3925–35. Available from: http://www.hubmed.org/display.cgi?uids=22972930.CrossRefPubMedPubMedCentral

26.

Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C, et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol. 2009;182:5982–93.CrossRefPubMedPubMedCentral

27.

Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood. 2005;105:4390–8.CrossRefPubMedPubMedCentral

28.

Zhang X. Regulatory functions of innate-like B cells. Cell Mol Immunol. 2013;10:113–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23396472.CrossRefPubMedPubMedCentral

29.

Plebani A, Lougaris V, Soresina A, Meini A, Zunino F, Losi CG, et al. A novel immunodeficiency characterized by the exclusive presence of transitional B cells unresponsive to CpG. Immunology. 2007;121:183–8.CrossRefPubMedPubMedCentral

30.

Siewe B, Stapleton JT, Martinson J, Keshavarzian A, Kazmi N, Demarais PM, et al. Regulatory B cell frequency correlates with markers of HIV disease progression and attenuates anti-HIV CD8⁺ T cell function in vitro. J Leukoc Biol. 2013;93:811–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23434518.CrossRefPubMedPubMedCentral

31.

Geffroy-Luseau A, Chiron D, Descamps G, Jégo G, Amiot M, Pellat-Deceunynck C. TLR9 ligand induces the generation of CD20+ plasmablasts and plasma cells from CD27+ memory B-cells. Front Immunol. 2011;2:83. Available from: http://journal.frontiersin.org/article/10.3389/fimmu.2011.00083/abstract.CrossRefPubMedPubMedCentral

Title: Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients
Authors: Xin Wei
Yangqiu Jin
Yinpu Tian
Huiyuan Zhang
Jie Wu
Wei Lu
Xiaofen Lu
Publication date: 01-05-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4538-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2016

Wnt5a and Ror2 expression associate with the disease progress of primary thyroid lymphoma

NIK- and IKKβ-binding protein promotes colon cancer metastasis by activating the classical NF-κB pathway and MMPs

Wnt/β-catenin signaling inhibits FBXW7 expression by upregulation of microRNA-770 in hepatocellular carcinoma

Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells

Roles of phosphatidylinositol 3-kinase regulatory subunit alpha, activator protein-1, and programmed cell death 4 in diagnosis of papillary thyroid carcinoma

FAM172A is a tumor suppressor in colorectal carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer